Toward gene therapy for Gaucher disease.

Area of Science:

• Hematology
• Gene Therapy
• Molecular Biology

Background:

• Genetic diseases of hematopoietic cells, like Gaucher disease, result from deficiencies in specific enzymes.
• Bone marrow transplantation is a potential treatment, but gene therapy offers an alternative approach.

Purpose of the Study:

• To investigate the transfer and expression of the human glucocerebrosidase (GC) gene into bone marrow cells using retroviral vectors.
• To evaluate the efficacy of this gene transfer as a model for gene therapy in genetic hematopoietic disorders, specifically Gaucher disease.

Main Methods:

• Development of a simple retroviral vector (G2) containing human GC cDNA.
• Transduction of murine bone marrow cells with the G2 vector, followed by long-term bone marrow culture (LTBMC) and transplantation into syngeneic recipients.
• Gene transfer studies using human bone marrow from a Gaucher disease patient, including prestimulation with growth factors and progenitor cell enrichment.

Main Results:

• High expression of the human GC gene was observed in transduced murine LTBMC cells, exceeding endogenous levels.
• Successful gene transfer and expression were detected in hematopoietic organs of recipient mice post-bone marrow transplant.
• Gene transfer into 35-40% of Gaucher patient hematopoietic progenitor cells was achieved, correcting the enzymatic deficiency.

Conclusions:

• Retroviral vector-mediated gene transfer is a viable strategy for the gene therapy of Gaucher disease.
• The study demonstrates the potential for correcting enzymatic deficiencies in hematopoietic stem cells.
• Further research is needed to ensure consistent in vivo expression and transduction of pluripotent human hematopoietic stem cells.